Want to see IN:BAFNAPH full AI Analyst Report?
Top Page
Bafna Pharmaceuticals Limited
(BAFNAPH)
Select Model
Select Model
Rating:54Neutral
Price Target:
₹417.00
▲(169.64% Upside)
Action:Reiterated
Date:10/08/26
The score is primarily constrained by weak cash-flow quality (negative free cash flow in most years) and uneven profitability despite strong revenue growth and a reasonably sound balance sheet. Technically, the stock shows a strong uptrend, but momentum is extremely overextended, increasing pullback risk. Valuation is a meaningful headwind given the very high P/E and no provided dividend yield.
Positive Factors
Long-term revenue expansion
Strong multi-year revenue expansion indicates that Bafna Pharmaceuticals has increased its business scale across its formulation markets. Continued top-line growth can support operating leverage, broader customer reach, and greater capacity to reinvest in products and distribution over the next several quarters.
Negative Factors
Persistently weak free cash flow
Negative free cash flow in most reported years indicates that investment and/or working-capital needs are absorbing cash despite reported profits. If this pattern persists, financial flexibility may remain constrained and the company could rely more heavily on external funding to sustain growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Long-term revenue expansion
Strong multi-year revenue expansion indicates that Bafna Pharmaceuticals has increased its business scale across its formulation markets. Continued top-line growth can support operating leverage, broader customer reach, and greater capacity to reinvest in products and distribution over the next several quarters.
Read all positive factors
Bafna Pharmaceuticals Limited (BAFNAPH) vs. iShares MSCI India ETF (INDA)
Market Cap
₹9.29B
Dividend Yield1.93%
Average Volume (3M)3.84K
Price to Earnings (P/E)119.8
Beta (1Y)0.63
Revenue Growth-3.14%
EPS Growth-5.80%
CountryIN
Employees339
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)3.29
Shares Outstanding23,656,336
10 Day Avg. Volume5,439
30 Day Avg. Volume3,839
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.69
Price to Sales (P/S)1.72
P/FCF Ratio-19.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bafna Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countrie...
How the Company Makes Money
Bafna Pharmaceuticals Limited makes money primarily by selling pharmaceutical formulations (finished dosage products) to customers in its served markets. Key revenue streams typically include (i) sales of branded or generic formulations through do...
Bafna Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
70
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.44B | 1.51B | 1.46B | 1.52B | 1.15B | 851.40M |
| Gross Profit | 329.05M | 201.42M | 168.77M | 452.15M | 175.56M | 137.18M |
| EBITDA | 163.50M | 207.04M | 117.73M | 146.34M | 189.88M | 112.34M |
| Net Income | 77.86M | 111.00M | 41.52M | 73.48M | 113.38M | 52.16M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.76B | 1.53B | 1.48B | 1.30B | 901.45M |
| Cash, Cash Equivalents and Short-Term Investments | 20.25M | 20.25M | 34.33M | 13.96M | 78.09M | 194.00K |
| Total Debt | 0.00 | 374.33M | 281.99M | 243.89M | 229.24M | 110.59M |
| Total Liabilities | -961.50M | 793.83M | 682.73M | 668.43M | 561.29M | 281.81M |
| Stockholders Equity | 961.50M | 961.50M | 848.07M | 808.39M | 734.55M | 619.64M |
Cash Flow | ||||||
| Free Cash Flow | -71.04M | -130.76M | -23.31M | -60.93M | -32.66M | 21.87M |
| Operating Cash Flow | 93.13M | 118.27M | 195.29M | 94.85M | 49.52M | 97.28M |
| Investing Cash Flow | -149.13M | -224.69M | -213.02M | -150.54M | -74.93M | -65.44M |
| Financing Cash Flow | 24.23M | 92.35M | 38.09M | -8.45M | 101.77M | -48.15M |
Bafna Pharmaceuticals Limited Technical Analysis
Positive
154.65
Price Trends
303.17
Positive
243.97
Positive
185.85
Positive
Market Momentum
29.54
Negative
87.99
Negative
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAFNAPH, the sentiment is Positive. The current price of 154.65 is below the 20-day moving average (MA) of 343.91, below the 50-day MA of 303.17, and below the 200-day MA of 185.85, indicating a bullish trend. The MACD of 29.54 indicates Negative momentum. The RSI at 87.99 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BAFNAPH.
Bafna Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹69.67B | 21.67 | ― | 4.03% | -8.88% | -10.68% | |
67 Neutral | ₹72.41B | 37.13 | ― | 0.11% | 28.14% | 11.38% | |
64 Neutral | ₹8.16B | 29.54 | ― | 0.40% | 14.04% | 2.57% | |
58 Neutral | ₹334.98B | 86.50 | ― | 1.27% | 18.37% | ― | |
56 Neutral | ₹26.44B | -82.80 | ― | 0.26% | -5.37% | -153.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹9.29B | 119.76 | ― | 1.93% | -3.14% | -5.80% |
* General Sector Average
IN:BAFNAPH
Bafna Pharmaceuticals Limited
408.55
244.30
148.74%
IN:HIKAL
Hikal Limited
224.90
-24.75
-9.91%
IN:KILITCH
Kilitch Drugs (India) Limited
256.15
76.95
42.94%
IN:SANOFI
Sanofi India Limited
3,024.80
-1,573.87
-34.22%
IN:SUPRIYA
Supriya Lifescience Limited
890.20
179.70
25.29%
IN:WOCKPHARMA
Wockhardt Limited
2,148.75
754.50
54.12%
Bafna Pharmaceuticals Limited Corporate Events
Bafna Pharmaceuticals Shuts Trading Window Ahead of Q2 FY27 Results
Sep 26, 2026
Bafna Pharmaceuticals Limited has announced the closure of its trading window for designated persons and their immediate relatives, in line with the SEBI (Prohibition of Insider Trading) Regulations and its own insider trading code. The window wil...
Bafna Pharmaceuticals Files SEBI Demat Compliance Certificate for June Quarter
Jul 9, 2026
Bafna Pharmaceuticals Limited, a Chennai-based drug maker listed on Indian exchanges, manufactures pharmaceuticals from its facilities in Tamil Nadu and relies on professional registrar and transfer agent services to handle its equity-related comp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.